Literature DB >> 35070401

Microsatellite instability in Chinese gastric cancer and its correlation with clinical characteristics.

Xinyu Li1, Lan Zhang2, Chunxiao Wang3, Junli Huang4, Jinfeng Zhu5, Yisen Huang6, Yifeng Chen7, Jing Jia1, Guozhong Jiang2.   

Abstract

BACKGROUND: Microsatellite instability (MSI) remains a focus of interest in cancer research, but the characteristics of MSI in gastric cancer (GC) are ambiguous.
METHODS: In this retrospective study, we analyzed the prevalence of MSI and the expression of programmed death-ligand 1 (PD-L1) and cluster of differentiation 8 (CD8) cells in Chinese GC patients. A total of 393 GC patients admitted to two centers from January 2010 to December 2017 were enrolled.
RESULTS: The prevalence of MSI in this cohort was 3.4% and most frequently occurred in females, patients aged between 59 and 69 years, and patients at a lower clinical stage. All MSI GCs had CD8 expression but lacked PD-L1 expression, indicating that MSI was related to CD8 expression but irrelevant to PD-L1 expression. However, there was no significant difference in the expression of CD8/PD-L1 between MSI GC and microsatellite stable (MSS) GC. Kaplan-Meier survival curves revealed that patients with MSI had a significantly longer overall survival (OS) than patients with MSS.
CONCLUSIONS: In Chinese GC patients, MSI frequently occurred in females, patients aged between 59 and 69, and patients with lower clinical stages. Patients with MSI-High (MSI-H) and MSI-Low (MSI-L) had a longer OS than patients with MSS. MSI was related to CD8 expression but irrelevant to PD-L1 expression. 2021 Journal of Gastrointestinal Oncology. All rights reserved.

Entities:  

Keywords:  CD8 expression; Gastric cancer (GC); immunotype; microsatellite instability (MSI); prognosis

Year:  2021        PMID: 35070401      PMCID: PMC8748045          DOI: 10.21037/jgo-21-695

Source DB:  PubMed          Journal:  J Gastrointest Oncol        ISSN: 2078-6891


  40 in total

1.  Phase III trial comparing capecitabine plus cisplatin versus capecitabine plus cisplatin with concurrent capecitabine radiotherapy in completely resected gastric cancer with D2 lymph node dissection: the ARTIST trial.

Authors:  Jeeyun Lee; Do Hoon Lim; Sung Kim; Se Hoon Park; Joon Oh Park; Young Suk Park; Ho Yeong Lim; Min Gew Choi; Tae Sung Sohn; Jae Hyung Noh; Jae Moon Bae; Yong Chan Ahn; Insuk Sohn; Sin Ho Jung; Cheol Keun Park; Kyoung-Mee Kim; Won Ki Kang
Journal:  J Clin Oncol       Date:  2011-12-19       Impact factor: 44.544

2.  Individual Patient Data Meta-Analysis of the Value of Microsatellite Instability As a Biomarker in Gastric Cancer.

Authors:  Filippo Pietrantonio; Rosalba Miceli; Alessandra Raimondi; Young Woo Kim; Won Ki Kang; Ruth E Langley; Yoon Young Choi; Kyoung-Mee Kim; Matthew Guy Nankivell; Federica Morano; Andrew Wotherspoon; Nicola Valeri; Myeong-Cherl Kook; Ji Yeong An; Heike I Grabsch; Giovanni Fucà; Sung Hoon Noh; Tae Sung Sohn; Sung Kim; Maria Di Bartolomeo; David Cunningham; Jeeyun Lee; Jae-Ho Cheong; Elizabeth Catherine Smyth
Journal:  J Clin Oncol       Date:  2019-09-12       Impact factor: 44.544

3.  Survival and prognosticators of gastric cancer that recurs after adjuvant chemotherapy with S-1.

Authors:  Toru Aoyama; Takaki Yoshikawa; Takafumi Watanabe; Tsutomu Hayashi; Takashi Ogata; Haruhiko Cho; Akira Tsuburaya
Journal:  Gastric Cancer       Date:  2011-02-16       Impact factor: 7.370

4.  Comprehensive molecular characterization of clinical responses to PD-1 inhibition in metastatic gastric cancer.

Authors:  Seung Tae Kim; Razvan Cristescu; Adam J Bass; Kyoung-Mee Kim; Justin I Odegaard; Kyung Kim; Xiao Qiao Liu; Xinwei Sher; Hun Jung; Mijin Lee; Sujin Lee; Se Hoon Park; Joon Oh Park; Young Suk Park; Ho Yeong Lim; Hyuk Lee; Mingew Choi; AmirAli Talasaz; Peter Soonmo Kang; Jonathan Cheng; Andrey Loboda; Jeeyun Lee; Won Ki Kang
Journal:  Nat Med       Date:  2018-07-16       Impact factor: 53.440

5.  Mismatch Repair Deficiency, Microsatellite Instability, and Survival: An Exploratory Analysis of the Medical Research Council Adjuvant Gastric Infusional Chemotherapy (MAGIC) Trial.

Authors:  Elizabeth C Smyth; Andrew Wotherspoon; Clare Peckitt; David Gonzalez; Sanna Hulkki-Wilson; Zakaria Eltahir; Matteo Fassan; Massimo Rugge; Nicola Valeri; Alicia Okines; Madeleine Hewish; William Allum; Sally Stenning; Matthew Nankivell; Ruth Langley; David Cunningham
Journal:  JAMA Oncol       Date:  2017-09-01       Impact factor: 33.006

Review 6.  Mismatch repair deficiency/microsatellite instability-high as a predictor for anti-PD-1/PD-L1 immunotherapy efficacy.

Authors:  Pengfei Zhao; Li Li; Xiaoyue Jiang; Qin Li
Journal:  J Hematol Oncol       Date:  2019-05-31       Impact factor: 17.388

7.  Comprehensive analysis of potential immunotherapy genomic biomarkers in 1000 Chinese patients with cancer.

Authors:  Yuan-Sheng Zang; Chun Dai; Xiaoman Xu; Xin Cai; Guan Wang; Jinwang Wei; Angela Wu; Wending Sun; Shunchang Jiao; Qiang Xu
Journal:  Cancer Med       Date:  2019-07-04       Impact factor: 4.452

8.  A model combining clinical and genomic factors to predict response to PD-1/PD-L1 blockade in advanced urothelial carcinoma.

Authors:  Amin H Nassar; Kent W Mouw; Opeyemi Jegede; Atul B Shinagare; Jaegil Kim; Chia-Jen Liu; Mark Pomerantz; Lauren C Harshman; Eliezer M Van Allen; Xiao X Wei; Bradley McGregor; Atish D Choudhury; Mark A Preston; Fei Dong; Sabina Signoretti; Neal I Lindeman; Joaquim Bellmunt; Toni K Choueiri; Guru Sonpavde; David J Kwiatkowski
Journal:  Br J Cancer       Date:  2019-12-20       Impact factor: 7.640

9.  Comprehensive molecular characterization of gastric adenocarcinoma.

Authors: 
Journal:  Nature       Date:  2014-07-23       Impact factor: 49.962

10.  High predictability for identifying Lynch syndrome via microsatellite instability testing or immunohistochemistry in all Lynch-associated tumor types.

Authors:  John M Carethers
Journal:  Transl Cancer Res       Date:  2019-12       Impact factor: 1.241

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.